Transgene SA: Trading Resumption and Successful €105 Million Capital Raise
Transgene SA (Euronext Paris: TNG) announced on 26 November 2025 that its shares will resume trading at the opening of the market. The suspension, which had been in place since 25 November 2025, was issued in anticipation of the publication of the company’s capital‑raising result.
The company completed a reserved offering that raised approximately €105 million. The transaction involved the issuance of new shares that reduced the ownership stake of existing shareholders from 78.29 % to 0.484 % of the fully diluted share capital. The fully diluted share count after the issuance increased from 214 664 113 to 275 191 778 shares, reflecting the new capital structure.
Key dates and actions:
- 25 November 2025 – Transgene requested Euronext Paris to suspend trading of its shares (ISIN FR0005175080) from 26 November 2025 at market open.
- 26 November 2025 – Trading resumed at the opening of the market. The company also confirmed the successful completion of the €105 million fundraising.
The capital raise was conducted through an over‑the‑counter private placement, and the proceeds are earmarked to support the development of the company’s therapeutic vaccines and oncolytic viruses targeting solid tumors, including lung, liver, head and neck, and colorectal cancers.
The fundraising was announced by Transgene’s corporate and scientific communications manager, Caroline Tosch, and its chief financial officer, Lucie Larguier. Investor relations contact Nadege Bartoli confirmed the transaction details.
The successful capital raise positions Transgene to accelerate clinical development of its immunotherapies and to enhance its research platform for recombinant virus design.
